WIXLIB

35THA N N U A LNew Treatmentsin ChronicLiver DiseaseM A I N C O N F E R ENCE: M A RCH 2 1 - 2 2 , 2 0 2 0Pre-Conference: March 20, 2020San Diego Mission Bay Resort San Diego, California

Course IntroductionCourse OverviewAccreditation & DisclosureThis CME conference will review new medications and therapies thatare now available, or will soon be available, and discuss their comparative values. The results of trials and real world data using oral drugs totreat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases,primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellularcarcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic LiverDisease is a comprehensive yet concise program for updating physicianson these and other commonly encountered problems in the treatmentof liver diseases.PhysiciansScripps Health is accredited by the AccreditationCouncil for Continuing Medical Education (ACCME) toprovide continuing medical education for physicians.Scripps Health designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s) . Physicians should only claim credit commensurate with theextent of their participation in the activity.In 2017, the World Health Organization released the Global HepatitisReport outlining the goals of viral eradication by 2030. This year we haveinvited Dr. John Ward, MD who is Head of the Viral Hepatitis Branch ofthe CDC to update the progress of the United States in accomplishingthese goals. Details of antiviral therapies will be discussed during paneldiscussions.New treatments which have been reported for both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC) will be discussedby Dr. Kris Kowdley from the Swedish Liver Center in Seattle, WA. We alsohave invited Dr. Constantine J. Karvellas, Assistant Professor, Division ofGastroenterology, Department of Critical Care Medicine at the Universityof Alberta to act as our William S. Haubrich Memorial Lecturer on thetopic of Acute Liver Failure. The course will also review alcoholic liverdisease and NASH, which have now surpassed chronic hepatitis C asthe leading indications for liver transplantation in the United States. Thefirst FDA-approved therapy for NASH is anticipated in 2020 and the datasupporting this FDA submission will be updated as well as the latestabstracts from AASLD 2019 on NASH. We have also invited a world-recognized expert on alcoholic liver disease to update our knowledge of thetopic this year. Our conference will include a lecture on diet and exerciseas management and prevention of obesity and fatty liver disease thisyear. We will also include a lecture on diagnosis and management ofbenign lesions of the liver given by an expert on this subject. And lastly,there will be a lecture devoted to the use of systemic therapies for hepatocellular carcinoma as there five approved drugs in the United States.Although hepatitis B treatments have not changed, we now have moremature data available on long-term HBsAg loss and clinical outcomes.The addition of immune-mediated therapies for HBV with the goal ofcuring the disease will also be included in this year’s program. New therapies for NAFLD and NASH are in development and important new datashowing positive results in NASH will be presented at this meeting, including the first results of a phase 3 global treatment trial. The explosivegrowth of NASH in the United States has created a significant need foreffective drug therapy. A number of new systemic therapies for HCCthat have been approved in the last two years will also be discussed.In addition, the course will provide updates on management of hepaticencephalopathy, hyponatremia, thrombocytopenia, and complications inthe transplant candidate.Credit BreakdownPre-Conference (Fri): 3.5Main Conference (Sat-Sun): 10ABIM MOC PointsSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.5 MOC pointsin the American Board of Internal Medicine’s (ABIM)Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amountof CME credits claimed for the activity. It is the CMEactivity provider’s responsibility to submit participantcompletion information to ACCME for the purpose ofgranting ABIM MOC credit. Please note: ABIM MOCpoints will be awarded to those who successfullycomplete the requirements outlined in the post-conference evaluation. Points earned will be reported tothe ABIM approximately 60 days post conference.These points will not appear on your CME certificatefrom Scripps.Board of Registered NursingFor the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1Credit(s) issued by organizations accredited by theACCME. For the purpose of re-licensure, the CaliforniaBoard of Registered Nursing accepts AMA PRA Category 1 Credit(s) . The majority of state boards acceptAMA PRA Category 1 Credit(s) as meeting continuing education requirements for license renewal. Nurses should check with their state’s Board of RegisteredNursing regarding use of CME credit.American Academy of Physician AssistantsPAs may claim a maximum of 13.5 Category 1 creditsfor completing this activity. NCCPA accepts AMA PRACategory 1 Credit from organizations accredited byACCME or a recognized state medical society.Commercial SupportThis course is supported, in part, by educational grantsfrom industry, in accordance with ACCME Accreditation Standards for Commercial Support. Appropriateacknowledgment will be given to all supporters at thetime of the educational activity.Educational ObjectivesAfter attending this live activity, participants should be able to: Identify the steps required to accomplish eradication of chronic viral hepatitis by 2030. Review current knowledge of NAFLD and non-alcoholic steatohepatitis and explore theuse of new agents and approaches to treatment of the conditions. Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals. Discuss diagnosis, management and treatment unusual hepatitis virus infections. Update the skills and management required for transplant hepatology. Apply current options of therapy for hepatocellular carcinoma to determine the bestapproach for your patients. Describe the diagnosis and treatment of PBC and PSC. Integrate treatment options discussed for patients with ESLD due to alcohol who havecomplicating factors such as HCV, NASH or inherited genetic disorders. Discuss the issues complicating drug treatment in decompensated cirrhosis, hepaticencephalopathy and hyponatremia. Update the diagnosis and management benign masses in the liver. Discuss the rising burden of alcoholic liver disease in the United States. Discuss advances in treatment of acute liver failure.

FacultyCourse DirectorsPaul J. Pockros, MD, FACGDirector, Liver Disease CenterScripps ClinicDirector of Clinical ResearchScripps Translational Science InstituteLa Jolla, CaliforniaCatherine T. Frenette, MD, FAST, AGAFMedical Director of Liver TransplantationScripps Center for Organ and Cell TransplantationDirector, Liver and Hepatocellular Cancer ProgramScripps MD Anderson Cancer CenterLa Jolla, CaliforniaConference FacultyTimothy J. Davern, MDDirector, Acute Liver Failure ProgramDivision, General and Transplant Hepatology DepartmentSan Francisco Center for Liver DiseaseSutter HealthSan Franciso, CaliforniaKen Fujioka, MDYuki Rosenkoetter, PAC, MPASDivision of Gastroenterology and HepatologyScripps ClinicLa Jolla, CaliforniaSammy Saab, MD, MPH, AGAF, FAASLD, FACGAdjunct Professor, Internal Medicine and SurgeryHead, Outcomes Research in HepatologyUniversity of California, Los AngelesLos Angeles, CaliforniaMitchell L Shiffman, MDDirector, Liver Institute of VirginiaBon Secours Mercy HealthRichmond, VirginiaNorman L. Sussman, MDAssociate Professor of Medicine and SurgeryDivision of Abdominal TransplantationMichael E. DeBakey Department of SurgeryBaylor College of MedicineHouston, TexasNorah A. Terrault, MD, MPHDirector, Nutrition and Metabolic Research CenterScripps ClinicLa Jolla, CaliforniaVisiting Professor of Medicine, ChiefDivision of Gastrointestinal and LiverKeck School of Medicine of USCLos Angeles, CaliforniaConstantine J. Karvellas, MD, SM, FRCPC, FCCMJohn W. Ward, MDAssociate Professor, Division of GastroenterologyDepartment of Critical Care MedicineAdjunct Professor, School of Public Health SciencesUniversity of AlbertaAlberta, CanadaKris V. Kowdley, MD, FACP, FACG, FASGE,AGAF, FAASLDDirector, Liver Care Network and Organ Care ResearchClinical Professor, College of MedicineWashington State UniversitySwedish Liver CenterSeattle, WashingtonSuthat Liangpunsakul, MDProfessor of Medicine, Biochemistry and Molecular BiologyIndiana University School of MedicineIndianapolis, IndianaDirector, Viral Hepatitis ProgramCenter for Disease Control and PreventionAtlanta, GeorgiaFaculty DisclosureIn accordance with the ACCME Standards for Commercial Support,course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose allrelevant financial relationships with any commercial interest that theyor their spouse/partner may have had within the past 12 months. If anindividual refuses to disclose relevant financial relationships, they willbe disqualified from being a part of the planning and implementationof this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CMEactivity will not be permitted to participate in the planning or executionof any accredited activity.A complete listing of disclosures associated with thisprogram can be found on the conference website:www.scripps.org/Livercme and in the mobile conference app: www.grupio.com/Liver20Pre-Conference AgendaFriday, March 20, 2020Pre-ConferenceAgenda12:30 p.m. Registration1 p.m. Welcome & IntroductionPaul J. Pockros, MD1:10 p.m. Epidemiology and Diagnosis Staging of NAFLDPaul J. Pockros, MD1:40 p.m. Current Treatment Option Including Diet and ExerciseCatherine T. Frenette, MD2:40 p.m. Break & View Exhibits3 p.m. New Drug Developments for NASHPaul J. Pockros, MD4 p.m. Case Presentation, Discussion and Q&AYuki Rosenkoetter, PAC, MPAS5 p.m.AdjournFriday, March 20, 202012:30 p.m. Registration1 p.m. Welcome & IntroductionPaul J. Pockros, MD1:10 p.m. Epidemiology and Diagnosis StagingPaul J. Pockros, MD